Scientific Validation of PROTON Magnetic Freezing Technology for Biomedical Cryopreservation

Efficient cryopreservation of cells and tissues is a central challenge in regenerative medicine and biobanking. Conventional techniques (slow freezing at -80°C °C or in liquid nitrogen) lead to the formation of damaging ice crystals and a significant loss of cell viability (only 30–50% of cells typically survive). PROTON magnetic freezing technology, developed by Ryoho Freeze Systems Co., combines controlled cold air (35 °C) with electromagnetic fields to align water molecules and generate uniform ice nanocrystals. This minimizes osmotic and structural damage during freezing. This article validates, through a review of clinical and experimental studies, the benefits of PROTON as a superior alternative to traditional cryogenic methods. In a variety of models – including iPS cell-derived dopaminergic neurospheres for Parkinson’s, fertilized oocytes, stem cells (iPS, ES, mesenchymal ADSCs), human tissues (skin, cornea), and even cryonics applications – PROTON has demonstrated post-thaw viability rates of up to 85–90%, with preservation of biological functionality and compliance with GMP /GLP standards. These results, supported by studies from leading institutions (Kyoto University, Univ. of the Ryukyus, NIBIOHN, Sumitomo Pharma), indicate that PROTON can redefine the standards of biomedical cryopreservation, offering greater efficacy and safety than cryopreservation in liquid nitrogen or at -80°C. °C.